An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures

Grants and Contracts Details

StatusFinished
Effective start/end date10/11/073/31/11

Funding

  • Eisai Incorporated: $40,942.00